Impact of Treatment With Colistin on Mortality Bacteremia Multiresistant Acinetobacter Baumannii Sensitive Colistin in Patients Critical

Completed

• Conditions: Acinetobacter Infections

• Registration Number: NCT02573064
• Lead Sponsor: Maimónides Biomedical Research Institute of Córdoba

Brief Summary

The present study was designed to study the impact of empirical treatment with colistin empirical monotherapy and combined treatment with tigecycline and vancomycin on mortality of bacteremia Multiresistant Acinetobacter Baumannii . The main objective was to evaluate the efficacy of empirical treatment with colistin and combined targeted therapy. The different therapeutical interventions were administered following the routine clinical practice in the medical centre and the investigator did not assign specific interventions to the subjects of the study.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-01
• Primary Completion: 2012-12
• Study First Submitted: 2015-08-28
• Status Verified: 2015-10
• Study First Submitted QC: 2015-10-08
• Last Update Submitted: 2015-10-08
• Study First Posted: 2015-10-09
• Last Update Posted: 2015-10-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 113

Inclusion Criteria

• Critics included patients ≥ 16 years with monomicrobial bloodstream infections by multiresistant acinetobacter baumannii to carbapenems and sensitive to colistin accompanied by systemic inflammatory response syndrome, provided they have received targeted treatment with colistin.

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
All-cause 30-day mortality (crude).	30 days

Secondary Outcome Measures

Name	Time	Method
All-cause 14 day mortality (crude).	14 days